FDA approves an immunotherapy combo after surgery for one type of colon cancer
Published
Tecentriq plus chemotherapy is now approved for stage III colon cancer with a certain genetic marker (dMMR). In the trial, it cut the risk of the cancer coming back or death by half compared with chemo alone.
Source: FDA
This is a plain-language summary. Read the original source for full details.